118 related articles for article (PubMed ID: 19966507)
1. Cilostazol increases tissue blood flow in contracting rabbit gastrocnemius muscle.
Fong M; Yoshitake M; Kambayashi J; Liu Y
Circ J; 2010 Jan; 74(1):181-7. PubMed ID: 19966507
[TBL] [Abstract][Full Text] [Related]
2. Interplay between inhibition of adenosine uptake and phosphodiesterase type 3 on cardiac function by cilostazol, an agent to treat intermittent claudication.
Wang S; Cone J; Fong M; Yoshitake M; Kambayashi Ji ; Liu Y
J Cardiovasc Pharmacol; 2001 Nov; 38(5):775-83. PubMed ID: 11602824
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells.
Cone J; Wang S; Tandon N; Fong M; Sun B; Sakurai K; Yoshitake M; Kambayashi J; Liu Y
J Cardiovasc Pharmacol; 1999 Oct; 34(4):497-504. PubMed ID: 10511123
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication.
Liu Y; Fong M; Cone J; Wang S; Yoshitake M; Kambayashi J
J Cardiovasc Pharmacol; 2000 Sep; 36(3):351-60. PubMed ID: 10975593
[TBL] [Abstract][Full Text] [Related]
5. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
Liu Y; Shakur Y; Yoshitake M; Kambayashi Ji J
Cardiovasc Drug Rev; 2001; 19(4):369-86. PubMed ID: 11830753
[TBL] [Abstract][Full Text] [Related]
6. A phosphodiesterase 3 inhibitor, K-134, improves hindlimb skeletal muscle circulation in rat models of peripheral arterial disease.
Yoshida H; Itoh S; Hara T; Sasaki Y; Kondo S; Nakagawa T; Asanuma A; Tanabe S
Atherosclerosis; 2012 Mar; 221(1):84-90. PubMed ID: 22269153
[TBL] [Abstract][Full Text] [Related]
7. The effects of cilostazol on nerve conduction velocity and blood flow: acute and chronic cauda equina compression in a canine model.
Sekiguchi M; Aoki Y; Konno S; Kikuchi S
Spine (Phila Pa 1976); 2008 Nov; 33(24):2605-11. PubMed ID: 19011541
[TBL] [Abstract][Full Text] [Related]
8. Effects of cilostazol lotion on blood flow in rabbit skin.
Ono I; Gunji H; Suda K; Kaneko F
J Dermatol Sci; 1994 Apr; 7(2):79-83. PubMed ID: 8060917
[TBL] [Abstract][Full Text] [Related]
9. Selective type III phosphodiesterase inhibition prevents elevated compartment pressure after ischemia/reperfusion injury.
Hakaim AG; Cunningham L; White JL; Hoover K
J Trauma; 1999 May; 46(5):869-72. PubMed ID: 10338405
[TBL] [Abstract][Full Text] [Related]
10. Differential effect of phosphodiesterase-3 inhibitors on sympathetic hyperinnervation in healed rat infarcts.
Lee TM; Lin SZ; Chang NC
Circ J; 2014; 78(2):366-76. PubMed ID: 24304537
[TBL] [Abstract][Full Text] [Related]
11. Cilostazol, an inhibitor of type 3 phosphodiesterase, produces endothelium-independent vasodilation in pressurized rabbit cerebral penetrating arterioles.
Nakamura K; Ikomi F; Ohhashi T
J Vasc Res; 2006; 43(1):86-94. PubMed ID: 16286783
[TBL] [Abstract][Full Text] [Related]
12. Induction of Angiogenesis by a Type III Phosphodiesterase Inhibitor, Cilostazol, Through Activation of Peroxisome Proliferator-Activated Receptor-γ and cAMP Pathways in Vascular Cells.
Sanada F; Kanbara Y; Taniyama Y; Otsu R; Carracedo M; Ikeda-Iwabu Y; Muratsu J; Sugimoto K; Yamamoto K; Rakugi H; Morishita R
Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):545-52. PubMed ID: 26769045
[TBL] [Abstract][Full Text] [Related]
13. New mechanism of action for cilostazol: interplay between adenosine and cilostazol in inhibiting platelet activation.
Sun B; Le SN; Lin S; Fong M; Guertin M; Liu Y; Tandon NN; Yoshitake M; Kambayashi J
J Cardiovasc Pharmacol; 2002 Oct; 40(4):577-85. PubMed ID: 12352320
[TBL] [Abstract][Full Text] [Related]
14. Effect of cilostazol, a phosphodiesterase type III inhibitor, on histamine-induced increase in [Ca2+]i and force in middle cerebral artery of the rabbit.
Shiraishi Y; Kanmura Y; Itoh T
Br J Pharmacol; 1998 Mar; 123(5):869-78. PubMed ID: 9535015
[TBL] [Abstract][Full Text] [Related]
15. A selective phosphodiesterase 3 inhibitor rescues low PO2-induced ATP release from erythrocytes of humans with type 2 diabetes: implication for vascular control.
Sprague RS; Bowles EA; Achilleus D; Stephenson AH; Ellis CG; Ellsworth ML
Am J Physiol Heart Circ Physiol; 2011 Dec; 301(6):H2466-72. PubMed ID: 21963837
[TBL] [Abstract][Full Text] [Related]
16. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle.
Tanaka T; Ishikawa T; Hagiwara M; Onoda K; Itoh H; Hidaka H
Pharmacology; 1988; 36(5):313-20. PubMed ID: 2841693
[TBL] [Abstract][Full Text] [Related]
17. Identification of interaction sites of cyclic nucleotide phosphodiesterase type 3A with milrinone and cilostazol using molecular modeling and site-directed mutagenesis.
Zhang W; Ke H; Colman RW
Mol Pharmacol; 2002 Sep; 62(3):514-20. PubMed ID: 12181427
[TBL] [Abstract][Full Text] [Related]
18. The pharmacology of cilostazol.
Schrör K
Diabetes Obes Metab; 2002 Mar; 4 Suppl 2():S14-9. PubMed ID: 12180353
[TBL] [Abstract][Full Text] [Related]
19. Cilostazol, a selective cAMP phosphodiesterase inhibitor, dilates retinal arterioles and increases retinal and choroidal blood flow in rats.
Hotta H; Ito H; Kagitani F; Sato A
Eur J Pharmacol; 1998 Feb; 344(1):49-52. PubMed ID: 9570447
[TBL] [Abstract][Full Text] [Related]
20. General pharmacological properties of cilostazol, a new antithrombotic drug. Part II: Effect on the peripheral organs.
Shintani S; Watanabe K; Kawamura K; Mori T; Tani T; Toba Y; Sasabe H; Nakagiri N; Hongoh O; Fujita S
Arzneimittelforschung; 1985; 35(7A):1163-72. PubMed ID: 3000392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
